Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Events
  5. Conferences

Conferences

Evaluate

Thumbnail
March 22, 2023

Second pivotal hit brings Claudin18.2 closer to approval

March 21, 2023

AACR 2023 – Moderna's immunotherapeutic splash

This year’s AACR meeting promises a surprising amount of clinical data relevant to biopharma investors.

Article image
Vantage logo
February 27, 2023

CROI 2023 – progress on efforts to cure HIV

Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure.

Article image
Vantage logo
February 17, 2023

Asco-GU – Talzenna remains a wait-and-see story in prostate cancer

Talapro-2 data backing Talzenna in all-comers are slated by Asco-GU’s discussant, as Lynparza shows precisely what might go wrong.

Article image
Vantage logo
February 15, 2023

Asco-GU – Bicycle tries to put distance between itself and Seagen

However, results with BT8009, one of several datasets being presented this week at the Asco-GU conference, fail to convince many investors.

Article image
Vantage logo
January 20, 2023

Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression

39% of the patients assessed carried this biomarker, the conference presentation reveals.

Article image
Vantage logo
January 20, 2023

Asco-GI 2023 – Keytruda looms over zanidatamab's second shot

Article image
Vantage logo
January 19, 2023

Asco-GI 2023 – zolbetuximab opens up a stomach cancer niche

Clinical data back Claudin18.2 as a target for treating stomach cancer – but biomarker diagnosis is needed.

Article image
Vantage logo
January 11, 2023

JP Morgan 2023 – Novartis and Gilead's interim halt hopes wane

Article image
Vantage logo
January 10, 2023

JP Morgan 2023 – Sutro makes its pitch to beat Immunogen

The group reckons it can target twice as many ovarian cancer patients, but an important disclosure shows that its case it not clear-cut.

Article image
Vantage logo
January 09, 2023

JP Morgan 2023 – day one sees buyers make the most of straitened times

Takeouts of Cincor, Albireo and Amryt emerge with contingent payment terms, as biopharma buyers flex their muscles.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up